mRNA evolves as a novel vaccine platform with unique advantages, such as quick production, low risk of genome integration, and high immunogenicity as can be seen from Moderna and Pfizer mRNA-based Covid-19 vaccines. Due to its high immunogenicity, no adjuvants have been added to further boost mRNA vaccine efficacy. Yet, adjuvants may be needed to develop mRNA vaccines against certain infectious diseases or cancer. As of such, this project explores effective adjuvants from currently available ones and develop novel adjuvants to safely and potently boost mRNA vaccination.